Home Tags Trastuzumab

Tag: trastuzumab

Featured Image Courtesy: Byondis Biopharmaceuticals (previously Synthon Biopharmaceuticals, Nijmegen, The Netherlands.

New Phase I Study Investigates [Vic-]Trastuzumab Duocarmazine + Niraparib in HER2-Expressing...

As part of a new study focusing on advanced targeting human epidermal growth factor receptor-2 (HER2-) expressing cancers, including locally advanced or metastatic solid...

U.S. Patent for Bolt Biotherapeutics’ Boltbody™ ISAC Platform Technology is a...

San Francisco Bay Area-based Bolt Biotherapeutics confirmed that the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent No. 10,675,358 entitled "Antibody Adjuvant...
Daiichi Sankyo

Daiichi Sankyo Submits Supplemental New Drug Application for Trastuzumab Deruxtecan in...

In a statement earlier today, Daiichi Sankyo confirmed that it has submitted a supplemental New Drug Application (sNDA) to Japan’s Ministry of Health, Labour...
Daiichi Sankyo

Daiichi Sankyo Accelerates BLA Submission for [Fam-] Trastuzumab Deruxtecan in HER2...

Earlier this week Daiichi Sankyo announced plans to accelerate filing of their Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA)...

Orphan Drug Designation for Alteogen’s Antibody-Drug Conjugate for the Treatment of...

Alteogen, a Korea-based biopharmaceutical company focusing on the development and commercialization of novel anticancer drugs such as antibody-drug conjugates, has received an approval for...

DS-8201 Receives SAKIGAKE Designation for Gastric Cancer from Japan’s Ministry of...

DS-8201, an investigational HER2-targeting antibody-drug conjugate or ADC being developed by Daiichi Sankyo, has received SAKIGAKE Designation for the treatment of HER2-positive advanced gastric...

Ongoing Phase I Trial of DS-8201 Demonstrates Confirmed Increased Overall Response...

Updated analysis from ongoing phase I study of DS-8201 (trastuzumab deruxtecan), an investigational HER2-targeting antibody-drug conjugate or ADC being developed by Daiichi Sankyo, demonstrated...

Breakthrough Therapy Designation for DS-8201 Confirms the Potential to Offer Substantial...

The U.S. Food and Drug Administration (FDA) earlier today confirmed that it has granted Breakthrough Therapy designation to DS-8201, an investigational HER2-targeting antibody-drug conjugate...

Study Shows Therapeutic Potential of an anti-HER2 single chain antibody–DM1 conjugates

In an attempt to develop a more effective therapy for human epidermal growth factor receptor 2 (HER2)-positive cancer, a team of researchers led by...

Anti-HER2 ADC SYD985 to be Evaluated in Expanded Cohort of HER2+...

Dutch pharmaceutical company Synthon Biopharmaceuticals has initiated the second part of an ongoing phase I clinical trial with its investigational anti-HER2 antibody-drug conjugate or ADC,...